{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:14:54Z","timestamp":1789809294706,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,4,18]],"date-time":"2010-04-18T00:00:00Z","timestamp":1271548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Maxillofac Surg"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s10006-010-0224-y","type":"journal-article","created":{"date-parts":[[2010,4,16]],"date-time":"2010-04-16T19:45:24Z","timestamp":1271447124000},"page":"63-66","source":"Crossref","is-referenced-by-count":103,"title":["Osteonecrosis of the jaw related to sunitinib"],"prefix":"10.1007","volume":"15","author":[{"given":"Felix P.","family":"Koch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,18]]},"reference":[{"key":"224_CR1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884\u2013896","journal-title":"J Clin Oncol"},{"key":"224_CR2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11864-007-0031-3","volume":"8","author":"NB Haas","year":"2007","unstructured":"Haas NB, Uzzo RG (2007) Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options in Oncol 8:211\u2013226","journal-title":"Curr Treat Options in Oncol"},{"key":"224_CR3","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res"},{"key":"224_CR4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971\u2013979","journal-title":"J Pharmacol Exp Ther"},{"key":"224_CR5","first-page":"1377","volume":"143","author":"C Sundberg","year":"1993","unstructured":"Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin C (1993) Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 143:1377\u20131388","journal-title":"Am J Pathol"},{"key":"224_CR6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/annonc\/mdn788","volume":"20","author":"J Ayllon","year":"2009","unstructured":"Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S (2009) Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 20:600\u2013601","journal-title":"Ann Oncol"},{"key":"224_CR7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","volume":"44","author":"A Brunello","year":"2009","unstructured":"Brunello A, Saia G, Bedogni A, Scaglione D, Basso U (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44:173\u2013175","journal-title":"Bone"},{"key":"224_CR8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","volume":"76","author":"C Christodoulou","year":"2009","unstructured":"Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209\u2013211","journal-title":"Oncology"},{"key":"224_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.joms.2003.11.009","volume":"62","author":"LA Assael","year":"2004","unstructured":"Assael LA (2004) New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg 62:125\u2013126","journal-title":"J Oral Maxillofac Surg"},{"key":"224_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10006-009-0198-9","volume":"14","author":"BR Chrcanovic","year":"2010","unstructured":"Chrcanovic BR, Reher P, Sousa AA, Harris M (2010) Osteoradionecrosis of the jaws\u2014a current overview\u2014part 1: physiopathology and risk and predisposing factors. Oral Maxillofac Surg 14:3\u201316","journal-title":"Oral Maxillofac Surg"},{"key":"224_CR11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3816\/SCT.2006.n.008","volume":"3","author":"CJ Langer","year":"2006","unstructured":"Langer CJ (2006) Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case report. Support Cancer Ther 3:122\u2013124","journal-title":"Support Cancer Ther"},{"key":"224_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00520-006-0120-z","volume":"15","author":"C Walter","year":"2007","unstructured":"Walter C, Grotz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15:197\u2013202","journal-title":"Support Care Cancer"},{"key":"224_CR13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10006-006-0017-5","volume":"10","author":"JU Piesold","year":"2006","unstructured":"Piesold JU, Al-Nawas B, Grotz KA (2006) Osteonecrosis of the jaws by long term therapy with bisphosphonates. Mund Kiefer Gesichtschir 10:287\u2013300","journal-title":"Mund Kiefer Gesichtschir"},{"key":"224_CR14","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.20.6.1692","volume":"20","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Blanke CD, Druker BJ, CC L (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692\u20131703","journal-title":"J Clin Oncol"},{"key":"224_CR15","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2174\/1381612043384394","volume":"10","author":"D Schmidt-Arras","year":"2004","unstructured":"Schmidt-Arras D, Schwable J, Bohmer FD, Serve H (2004) Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des 10:1867\u20131883","journal-title":"Curr Pharm Des"},{"key":"224_CR16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16\u201324","journal-title":"J Clin Oncol"},{"key":"224_CR17","unstructured":"Wolter P, Dumez H, Schoffski P (2007) Sunitinib and hypothyroidism. N Engl J Med 356:1580; author reply 1580\u20131581"},{"key":"224_CR18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","volume":"3","author":"JM Roodhart","year":"2008","unstructured":"Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway. Curr Clin Pharmacol 3:132\u2013143","journal-title":"Curr Clin Pharmacol"},{"key":"224_CR19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/archderm.144.1.123","volume":"144","author":"P Suwattee","year":"2008","unstructured":"Suwattee P, Chow S, Berg BC, Warshaw EM (2008) Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol 144:123\u2013125","journal-title":"Arch Dermatol"},{"key":"224_CR20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25\u201335","journal-title":"J Clin Oncol"},{"key":"224_CR21","first-page":"S41","volume":"1","author":"C Kollmannsberger","year":"2007","unstructured":"Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G (2007) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1:S41\u2013S54","journal-title":"Can Urol Assoc J"},{"key":"224_CR22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.eururo.2008.06.070","volume":"54","author":"C Walter","year":"2008","unstructured":"Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066\u20131072","journal-title":"Eur Urol"},{"key":"224_CR23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00428-007-0516-2","volume":"451","author":"T Hansen","year":"2007","unstructured":"Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ (2007) Actinomycosis of the jaws\u2014histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451:1009\u20131017","journal-title":"Virchows Arch"},{"key":"224_CR24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/hed.2890040313","volume":"4","author":"HC Schwartz","year":"1982","unstructured":"Schwartz HC (1982) Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 4:251\u2013253","journal-title":"Head Neck Surg"},{"key":"224_CR25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF00314866","volume":"42","author":"P Marquet","year":"1992","unstructured":"Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F, Nicot G (1992) Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42:545\u2013547","journal-title":"Eur J Clin Pharmacol"},{"key":"224_CR26","first-page":"257","volume":"28","author":"A Billiau","year":"1981","unstructured":"Billiau A (1981) Pharmacokinetic and pharmacological aspects of interferon therapy in man. Acta Microbiol Acad Sci Hung 28:257\u2013262","journal-title":"Acta Microbiol Acad Sci Hung"}],"container-title":["Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-010-0224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10006-010-0224-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-010-0224-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T03:06:37Z","timestamp":1559099197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10006-010-0224-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,18]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["224"],"URL":"https:\/\/doi.org\/10.1007\/s10006-010-0224-y","relation":{},"ISSN":["1865-1550","1865-1569"],"issn-type":[{"value":"1865-1550","type":"print"},{"value":"1865-1569","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,18]]}}}